Mind Medicine Australia has provided funding for two studies that will be investigating the use of psilocybin and MDMA.
Reset Mind Sciences, a wholly-owned subsidiary of Little Green Pharma, has received Human Research Ethics Committee (HREC) approval for a trial investigating psilocybin-assisted psychotherapy for the...
For the next two weeks, a digital poster campaign will be featured in London asking the UK public “Could magic mushrooms be medicine?”.
COMPASS Pathways is recruiting participants for its trial investigating the safety and tolerability of its psilocybin formula – COMP360 – for post-traumatic stress disorder (PTSD).
Optimi Health has submitted an application to carry out a Phase I clinical trial investigating the safety of the combinatory use of psilocybin and MDMA in...
In a groundbreaking development, Australia is to reclassify psilocybin and MDMA to enable prescribing by authorised psychiatrists.
Diamond Therapeutics has received approval from Health Canada to carry out a Phase 2 low-dose psilocybin trial for the treatment of generalised anxiety disorder (GAD) on...
Psyence Group has confirmed that it has exported purified pharmaceutical-grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (CDMO) partner in the UK.
Incannex Healthcare has confirmed that its PsiGAD1 clinical trial has achieved its interim milestone of 29 patients completing primary endpoint assessments.
Silo Pharma is advancing its clinical study exploring psilocybin’s effect on inflammation, targeting conditions such as Parkinson’s disease, bipolar disorder and chronic pain.